Ross Connor J, Ghauri Sophia, Gilbert Joshua B, Hu Daniel, Ullanat Varun, Gong Dan, Greenberg Paul B, Eliott Dean, Elze Tobias, Lorch Alice, Miller Joan W, Krzystolik Magdalena G
Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Division of Ophthalmology, Warren Alpert Medical School, Brown University, Providence, Rhode Island.
Ophthalmol Retina. 2025 Mar;9(3):224-231. doi: 10.1016/j.oret.2024.09.002. Epub 2024 Sep 10.
To determine if intravitreal injection of antibiotics alone versus early pars plana vitrectomy (PPV) plus injection of intravitreal antibiotics predicted better or worse visual outcomes for patients with endophthalmitis after anti-VEGF injections.
Retrospective cohort study.
Patients developing endophthalmitis after receiving an intravitreal anti-VEGF injection from the American Academy of Ophthalmology IRIS® (Intelligent Research in Sight) Registry between 2016 and 2020.
Inclusion criteria were endophthalmitis diagnosis within 1 to 28 days after anti-VEGF injection and a recorded visual acuity (VA) at baseline, on the day of diagnosis, and posttreatment. Patients in the Injection Only group underwent intravitreal injection of antibiotics alone and in the Early Vitrectomy group received PPV with intravitreal antibiotics or intravitreal injection followed by PPV within 2 days of diagnosis. Patients were excluded if they had cataract surgery during the study, intravitreal steroids before endophthalmitis, or intermediate/posterior uveitis or cystoid macular edema. The study created a 1:1 matched cohort using Mahalanobis distance matching, accounting for the differences in VA at baseline and diagnosis.
Posttreatment logarithm of the minimum angle of resolution (logMAR) VA.
A total of 1044 patients diagnosed with postinjection endophthalmitis met the inclusion and exclusion criteria. In the unmatched cohort, there were 935 patients in the Injection Only and 109 in the Early Vitrectomy group. In 1:1 matched cohort, 218 patients (109 in each group) were included; the median logMAR VAs were 0.32 (20/40-20/50) at baseline, 0.88 (∼20/150) at diagnosis, and 0.57 (20/70-20/80) posttreatment. There were no statistically significant differences in the visual outcomes between the 2 matched treatment groups (b = 0.05; P = 0.23); including the subgroup of patients with VA worse than 1.0 logMAR (b = 0.05; P = 0.452).
There was no significant difference in final VA outcomes between patients receiving Injection Only and those treated with Early Vitrectomy for postinjection endophthalmitis. The findings support the use of either treatment strategy.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
确定单纯玻璃体内注射抗生素与早期玻璃体切割术(PPV)联合玻璃体内注射抗生素相比,对接受抗VEGF注射后发生眼内炎的患者视觉预后的影响是更好还是更差。
回顾性队列研究。
2016年至2020年间在美国眼科学会IRIS®(智能视力研究)注册中心接受玻璃体内抗VEGF注射后发生眼内炎的患者。
纳入标准为抗VEGF注射后1至28天内诊断为眼内炎,且在基线、诊断当天和治疗后记录有视力(VA)。单纯注射组患者仅接受玻璃体内注射抗生素,早期玻璃体切割术组患者在诊断后2天内接受PPV联合玻璃体内抗生素或先进行玻璃体内注射,随后进行PPV。如果患者在研究期间接受了白内障手术、眼内炎发生前接受了玻璃体内类固醇注射、或患有中间/后部葡萄膜炎或黄斑囊样水肿,则将其排除。该研究使用马氏距离匹配法创建了1:1匹配队列,考虑了基线和诊断时VA的差异。
治疗后最小分辨角对数(logMAR)视力。
共有1044例诊断为注射后眼内炎的患者符合纳入和排除标准。在未匹配队列中,单纯注射组有935例患者,早期玻璃体切割术组有109例患者。在1:1匹配队列中,纳入了218例患者(每组109例);基线时logMAR视力中位数为0.32(20/40 - 20/50),诊断时为0.88(约20/150),治疗后为0.57(20/70 - 20/80)。两个匹配治疗组之间的视觉预后无统计学显著差异(b = 0.05;P = 0.23);包括视力比1.0 logMAR差的患者亚组(b = 0.05;P = 0.452)。
对于注射后眼内炎患者,单纯注射组与接受早期玻璃体切割术组的最终视力预后无显著差异。这些发现支持使用任何一种治疗策略。
本文末尾的脚注和披露中可能会有专有或商业披露信息。